Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.01
+0.02 (0.40%)
At close: Oct 29, 2025, 4:00 PM EDT
4.990
-0.020 (-0.40%)
Pre-market: Oct 30, 2025, 8:46 AM EDT
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $1.99M in the quarter ending June 30, 2025, with 78.60% growth. This brings the company's revenue in the last twelve months to $8.10M, down -37.09% year-over-year. In the year 2024, Taysha Gene Therapies had annual revenue of $8.33M, down -46.07%.
Revenue (ttm)
$8.10M
Revenue Growth
-37.09%
P/S Ratio
170.75
Revenue / Employee
$110,932
Employees
73
Market Cap
1.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TSHA News
- 2 days ago - Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - GlobeNewsWire
- 13 days ago - Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome - GlobeNewsWire
- 21 days ago - Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - GlobeNewsWire
- 23 days ago - Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential - Seeking Alpha
- 26 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire